<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:50:09Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7145588" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7145588</identifier>
        <datestamp>2021-04-10</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="pmc">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>American Society of Clinical Oncology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7145588</article-id>
              <article-id pub-id-type="pmcid">PMC7145588</article-id>
              <article-id pub-id-type="pmc-uid">7145588</article-id>
              <article-id pub-id-type="pmid">31961766</article-id>
              <article-id pub-id-type="pmid">31961766</article-id>
              <article-id pub-id-type="publisher-id">1901598</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.19.01598</article-id>
              <article-categories>
                <subj-group subj-group-type="subjects">
                  <compound-subject>
                    <compound-subject-part content-type="code">GUC</compound-subject-part>
                    <compound-subject-part content-type="label">GENITOURINARY: BLADDER &amp; UROTHELIAL</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">GUC</compound-subject-part>
                    <compound-subject-part content-type="label">KIDNEY</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">GYNC</compound-subject-part>
                    <compound-subject-part content-type="label">GYNECOLOGIC: OTHER GYNECOLOGIC TUMORS</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">HNC</compound-subject-part>
                    <compound-subject-part content-type="label">HEAD AND NECK</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">MELA</compound-subject-part>
                    <compound-subject-part content-type="label">MELANOMA</compound-subject-part>
                  </compound-subject>
                  <compound-subject>
                    <compound-subject-part content-type="code">THOR</compound-subject-part>
                    <compound-subject-part content-type="label">THORACIC ONCOLOGY: LUNG</compound-subject-part>
                  </compound-subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Clinical Trials</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors</article-title>
                <alt-title alt-title-type="short">Lenvatinib Plus Pembrolizumab in Advanced Solid Tumors</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Matthew H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff1">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor1"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Chung-Han</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Makker</surname>
                    <given-names>Vicky</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rasco</surname>
                    <given-names>Drew</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff3">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dutcus</surname>
                    <given-names>Corina E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Jane</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stepan</surname>
                    <given-names>Daniel E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff5">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shumaker</surname>
                    <given-names>Robert C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="aff4">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Motzer</surname>
                    <given-names>Robert J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Knight Cancer Institute, Oregon Health and Science University, Portland, OR</aff>
                <aff id="aff2"><label><sup>2</sup></label>Memorial Sloan Kettering Cancer Center, New York, NY</aff>
                <aff id="aff3"><label><sup>3</sup></label>START, San Antonio, TX</aff>
                <aff id="aff4"><label><sup>4</sup></label>Eisai Inc, Woodcliff Lake, NJ</aff>
                <aff id="aff5"><label><sup>5</sup></label>Formerly of Eisai Inc, Woodcliff Lake, NJ</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Matthew H. Taylor, MD, Knight Cancer Institute, Oregon Health and Science University, 3303 SW Bond Ave, Portland, OR 97239; e-mail: <email>taylmatt@ohsu.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>4</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>1</month>
                <year>2020</year>
              </pub-date>
              <volume>38</volume>
              <issue>11</issue>
              <fpage>1154</fpage>
              <lpage>1163</lpage>
              <history>
                <date date-type="accepted">
                  <day>21</day>
                  <month>11</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2020 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:title="pdf" xlink:href="JCO.19.01598.pdf"/>
              <abstract>
                <sec>
                  <title>PURPOSE</title>
                  <p>Modulation of vascular endothelial growth factor–mediated immune suppression via angiogenesis inhibition may augment the activity of immune checkpoint inhibitors. We report results from the dose-finding and initial phase II expansion of a phase Ib/II study of lenvatinib plus pembrolizumab in patients with selected advanced solid tumors.</p>
                </sec>
                <sec>
                  <title>METHODS</title>
                  <p>Eligible patients had metastatic renal cell carcinoma (RCC), endometrial cancer, squamous cell carcinoma of the head and neck (SCCHN), melanoma, non–small-cell lung cancer (NSCLC), or urothelial cancer. The primary objective of phase Ib was to determine the maximum tolerated dose (MTD) for lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks). In the preplanned phase II cohort expansion, the primary objective was objective response rate at week 24 (ORR<sub>week 24</sub>) at the recommended phase II dose.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>Overall, 137 patients were enrolled during phase Ib (n = 13) and the initial phase II expansion (n = 124). Two dose-limiting toxicities (DLTs; grade 3 arthralgia and grade 3 fatigue) were reported in the initial dose level (lenvatinib 24 mg/d plus pembrolizumab). No DLTs were observed in the subsequent dose–de-escalation cohort, establishing the MTD and recommended phase II dose at lenvatinib 20 mg/d plus pembrolizumab. ORR<sub>week24</sub> was as follows: RCC, 63% (19/30; 95% CI, 43.9% to 80.1%); endometrial cancer, 52% (12/23; 95% CI, 30.6% to 73.2%); melanoma, 48% (10/21; 95% CI, 25.7% to 70.2%); SCCHN, 36% (8/22; 95% CI, 17.2% to 59.3%); NSCLC, 33% (7/21; 95% CI, 14.6% to 57.0%); and urothelial cancer 25% (5/20; 95% CI, 8.7% to 49.1%). The most common treatment-related adverse events were fatigue (58%), diarrhea (52%), hypertension (47%), and hypothyroidism (42%).</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>Lenvatinib plus pembrolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with selected solid tumor types.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="subject_thes">
                <compound-kwd>
                  <compound-kwd-part content-type="term">3282-3306-7927-3999</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Vascular endothelial growth factor</compound-kwd-part>
                  <compound-kwd-part content-type="hits">12</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-252-4035</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Endometrial neoplasms</compound-kwd-part>
                  <compound-kwd-part content-type="hits">11</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-147-2338</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Head and neck squamous cell carcinoma</compound-kwd-part>
                  <compound-kwd-part content-type="hits">11</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-8931</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Dose reduction</compound-kwd-part>
                  <compound-kwd-part content-type="hits">11</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">298-145-222-184-1022-9124</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Phase II trials</compound-kwd-part>
                  <compound-kwd-part content-type="hits">10</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">261-566-9263</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Monotherapy</compound-kwd-part>
                  <compound-kwd-part content-type="hits">10</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-232</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Melanoma</compound-kwd-part>
                  <compound-kwd-part content-type="hits">9</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">281-318-9082</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Advanced disease</compound-kwd-part>
                  <compound-kwd-part content-type="hits">4</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-147-2338</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Head and neck squamous cell carcinoma</compound-kwd-part>
                  <compound-kwd-part content-type="hits">3</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-197-481</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Non small cell lung carcinoma</compound-kwd-part>
                  <compound-kwd-part content-type="hits">3</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">613-225-2577-2545</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Maximum tolerable dose</compound-kwd-part>
                  <compound-kwd-part content-type="hits">3</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-324</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Solid tumors</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-424-3231</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Renal cell carcinoma</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-252-4035</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Endometrial neoplasms</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">283-183-138</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">Urothelial cancer</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
              </kwd-group>
              <kwd-group kwd-group-type="drug_thes">
                <compound-kwd>
                  <compound-kwd-part content-type="term">28</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">lenvatinib</compound-kwd-part>
                  <compound-kwd-part content-type="hits">45</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">242</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">pembrolizumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">33</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">28</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">lenvatinib</compound-kwd-part>
                  <compound-kwd-part content-type="hits">5</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">242</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">pembrolizumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">5</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">28</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">lenvatinib</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">242</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">pembrolizumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">319</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">axitinib</compound-kwd-part>
                  <compound-kwd-part content-type="hits">2</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">307</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">everolimus</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
                <compound-kwd>
                  <compound-kwd-part content-type="term">1880</compound-kwd-part>
                  <compound-kwd-part content-type="thesTerm">avelumab</compound-kwd-part>
                  <compound-kwd-part content-type="hits">1</compound-kwd-part>
                </compound-kwd>
              </kwd-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <equation-count count="0"/>
                <ref-count count="37"/>
                <page-count count="11"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name> SJS Export </meta-name>
                  <meta-value>v1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>Vascular endothelial growth factor (VEGF), a regulator of angiogenesis in solid malignancies, is an important target in anticancer therapy.<sup><xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref></sup> VEGF also affects immune suppression by promoting the expansion of suppressive immune cell populations, such as regulatory T cells and myeloid-derived suppressor cells.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> VEGF suppresses effector T cell development, recruits tumor-associated macrophages to the tumor site, and inhibits the maturation and stimulatory function of dendritic cells.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> This causes inadequate presentation of tumor antigens, resulting in the impaired induction of T-cell–mediated immune responses directed at tumor antigens.<sup><xref rid="B3" ref-type="bibr">3</xref></sup></p>
              <p>Preclinical and clinical studies suggest that modulation of VEGF-mediated immune suppression via angiogenesis inhibition could potentially augment the immunotherapeutic activity of immune checkpoint inhibitors.<sup><xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B5" ref-type="bibr">5</xref></sup> Lenvatinib is a multitargeted tyrosine kinase inhibitor of VEGF receptor 1-3, fibroblast growth factor (FGF) receptor 1-4, platelet-derived growth factor receptor α, RET, and KIT.<sup><xref rid="B6" ref-type="bibr">6</xref>-<xref rid="B8" ref-type="bibr">8</xref></sup> Of note, upregulation of FGF has been described as a resistance mechanism to VEGF inhibition.<sup><xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref></sup> As such, the combined inhibition of VEGF and FGF signaling may contribute to the therapeutic efficacy of lenvatinib.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> Studies in mouse tumor models showed that treatment with lenvatinib combined with an anti–programmed cell death-1 (PD-1) monoclonal antibody demonstrated superior antitumor activity compared with either compound individually.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B12" ref-type="bibr">12</xref></sup> These studies provide a strong rationale for the combination of lenvatinib plus pembrolizumab, an anti-PD-1 monoclonal antibody capable of producing significant antitumor immune responses in various solid tumors.<sup><xref rid="B13" ref-type="bibr">13</xref></sup></p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>METHODS</title>
              <sec id="s3">
                <title>Study Design and Treatment</title>
                <p>This phase Ib/II, multicenter, open-label study was designed to evaluate the safety, tolerability, and antitumor activity of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma (RCC), endometrial cancer, melanoma, squamous cell carcinoma of the head and neck (SCCHN), non–small-cell lung cancer (NSCLC), and urothelial cancer (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02501096">NCT02501096</ext-link>). The tumor types were selected based on preliminary evidence of efficacy with lenvatinib and/or a PD-1 inhibitor in other studies where the agents were individually administered.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B12" ref-type="bibr">12</xref></sup></p>
                <p>The maximum tolerated dose (MTD) was investigated in the phase Ib dose-finding portion of the study using a dose–deescalation strategy with a 3 + 3 design (Data Supplement). In the phase II portion of the study, all patients received the recommended phase II dose of lenvatinib 20 mg/day with pembrolizumab 200 mg every 3 weeks until disease progression or development of unacceptable toxicity.</p>
                <p>The protocol was approved by the relevant institutional review boards or ethics committees and was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. All patients provided written informed consent prior to study enrollment.</p>
              </sec>
              <sec id="s4">
                <title>Patients</title>
                <p>Key eligibility criteria for phase Ib included histologically or cytologically confirmed metastatic RCC, endometrial cancer, melanoma, SCCHN, NSCLC, or urothelial cancer that progressed after approved therapies or for which no standard therapies were available. There was no limit on the number of prior anticancer therapies during the phase Ib portion of the trial. Key entry criteria for phase II included age ≥ 18 years, measurable disease according to immune-related Response Evaluation Criteria in Solid Tumors (irRECIST),<sup><xref rid="B14" ref-type="bibr">14</xref></sup> ≤ 2 prior lines of systemic therapies, Eastern Cooperative Oncology Group performance status score of 0 or 1, blood pressure ≤ 150/90 mmHg, and adequate bone marrow, hepatic, and renal function. Patients were not preselected based on any biomarker, including microsatellite instability or programmed cell death-ligand 1 (PD-L1) expression. Key exclusion criteria included prior anticancer treatment within 28 days of the first dose of study drugs, significant cardiovascular impairment, inadequate recovery from toxicities and/or complications resulting from major surgery, and prior therapy with lenvatinib.</p>
              </sec>
              <sec id="s5">
                <title>Clinical Assessments</title>
                <p>The primary objective for phase Ib was to determine the MTD and recommended phase II dose for lenvatinib plus pembrolizumab. The phase II primary endpoint was objective response rate at 24 weeks (ORR<sub>week24</sub>), which was defined as best overall response as of week 24. Secondary endpoints for phase II included the overall objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR).</p>
                <p>Tumor responses were evaluated based on investigator assessment per irRECIST using computed tomography or magnetic resonance imaging.<sup><xref rid="B14" ref-type="bibr">14</xref></sup> Complete and partial responses were confirmed no less than 4 weeks after the initial response. Tumor assessments were performed at baseline, every 6 weeks until week 24, and every 9 weeks thereafter. Radiographic evidence of disease progression was confirmed with repeat imaging at least 4 weeks later. Additional methods are included in the Data Supplement.</p>
              </sec>
              <sec id="s6">
                <title>Statistical Analysis</title>
                <p>The total number of patients required for the phase Ib portion of this study was dependent on the toxicities observed as the study progressed. A sample size of approximately 10 to 30 patients in phase Ib was planned to assess the MTD. For the phase II portion of the study, a sample size of 10 patients was enrolled per cohort, with the possibility of expansion to 20 patients per cohort based on sponsor and investigator evaluation of the efficacy and safety results observed with the initial 10 patients.</p>
                <p>The point estimates of response rates and their 2-sided 95% CIs were calculated using the Clopper-Pearson method. Median PFS and DOR and their 2-sided 95% CIs were estimated using the Kaplan-Meier method. All statistical analyses were performed using SAS version 9.0 or higher (SAS Institute, Cary NC).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s7">
              <title>RESULTS</title>
              <sec id="s8">
                <title>Patients</title>
                <p>Between July 31, 2015, and March 1, 2018, 137 patients were enrolled at 7 centers in the United States. Thirty patients (22%) had RCC, 23 (17%) had endometrial cancer, 22 (16%) had SCCHN, 21 (15%) had melanoma, 21 (15%) had NSCLC, and 20 (15%) had urothelial cancer (<xref rid="T1" ref-type="table">Table 1</xref>). Most patients (75%) received at least 1 prior systemic therapy before enrollment. The list of prior treatments received by patients is presented in the Data Supplement. At the time of data cutoff (March 1, 2018), 30 patients (22%) were still receiving treatment, and 107 (78%) had discontinued treatment. Sixty-three patients (46%) discontinued treatment because of disease progression, and 27 (20%) discontinued because of adverse events (AEs).</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Baseline Demographic and Clinical Characteristics by Tumor Type</p>
                  </caption>
                  <graphic xlink:href="JCO.19.01598t1"/>
                </table-wrap>
              </sec>
              <sec id="s9">
                <title>Determination of MTD/Recommended Phase II Dose</title>
                <p>Two dose-limiting toxicities (DLTs) were observed in the dose-finding portion of the study in 3 patients (RCC, n = 2; NSCLC, n = 1) who received the initial starting dose of lenvatinib 24 mg/day and pembrolizumab 200 mg. DLTs consisted of grade 3 arthralgia and grade 3 fatigue. No DLTs were observed in the 10 patients enrolled in the subsequent cohort treated with lenvatinib 20 mg/day plus pembrolizumab 200 mg every 3 weeks. Therefore, oral lenvatinib 20 mg/day and intravenous pembrolizumab 200 mg every 3 weeks was established as the MTD and the recommended phase II dose.</p>
              </sec>
              <sec id="s10">
                <title>Safety</title>
                <p>Treatment-related AEs (TRAEs) were reported in 97% (133/137) of patients (<xref rid="T2" ref-type="table">Table 2</xref>). Because AEs were similar across the cohorts, the overall safety profile is described in aggregate (Data Supplement). The most common any-grade TRAEs across all cohorts were fatigue (58%; 79/137), diarrhea (52%; 71/137), hypertension (47%; 64/137), hypothyroidism (42%; 58/137), and decreased appetite (39%; 54/137). Grade 3-4 TRAEs were reported in 67% (92/137) of patients. The most common grade 3-4 TRAEs across all cohorts were hypertension (20%; 28/137), fatigue (12%; 17/137), diarrhea (9%; 12/137), proteinuria (8%; 11/137), and increased lipase levels (7%; 9/137; <xref rid="T2" ref-type="table">Table 2</xref>).</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Summary of Treatment-Related AEs (any-grade frequency of ≥ 10%, grade 3 frequency of ≥ 2%, and all grade 4)</p>
                  </caption>
                  <graphic xlink:href="JCO.19.01598t2"/>
                </table-wrap>
                <p>TRAEs resulted in the following treatment modifications: lenvatinib dose reduction and/or interruption (85%; 116/137), lenvatinib discontinuation (13%; 18/137), pembrolizumab dose interruption (45%; 62/137), and pembrolizumab discontinuation (15%; 20/137; <xref rid="T2" ref-type="table">Table 2</xref>). The most common AEs reported as reasons for lenvatinib dose reduction and/or interruption were fatigue (26%; 35/137), diarrhea (23%; 31/137), hypertension (17%; 23/137), decreased appetite (16%; 22/137), and proteinuria (11%; 15/137). The most common AEs leading to pembrolizumab dose interruption were fatigue (10%; 13/137), diarrhea (7%; 10/137), decreased appetite (5%; 7/137), dyspnea (4%; 5/137), and nausea (4%; 4/137). Of the 5 patients with dyspnea, 1 patient experienced pneumonitis. AEs leading to lenvatinib or pembrolizumab discontinuation are shown in the Data Supplement.</p>
                <p>In total, 21 deaths occurred in the study. Two were deemed treatment related: 1 patient with NSCLC (pulmonary hemorrhage) and 1 patient with urothelial cancer (gastrointestinal hemorrhage).</p>
                <p>Prespecified AEs of special interest (ie, previously associated with drug exposure) were recorded also. For pembrolizumab, these were considered to be immune mediated. Potentially immune related, TRAEs occurred in 52% (71/137) of patients; grade 3 or 4 immune-related AEs occurred in 8% (11/137) and 2% (2/137) of patients, respectively (<xref rid="T3" ref-type="table">Table 3</xref>). The most common immune-related grade 3 and 4 TRAEs of special interest for pembrolizumab were adrenal insufficiency and colitis (1.5% each).</p>
                <table-wrap id="T3" orientation="portrait" position="float">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Potentially Immune-Related Adverse Events</p>
                  </caption>
                  <graphic xlink:href="JCO.19.01598t3"/>
                </table-wrap>
                <p>TRAEs of special interest for lenvatinib occurred in 80% (110/137) of patients; grade 3 or 4 TRAEs of special interest occurred in 33% (45/137) and 2% (3/137) of patients, respectively. The most common grade 3 and 4 TRAEs of special interest for lenvatinib were hypertension (20%), AST increased, ALT increased, and palmar-plantar erythrodysesthesia syndrome (2% each).</p>
              </sec>
              <sec id="s11">
                <title>Efficacy</title>
                <p>Among patients in the RCC cohort, the primary endpoint of ORR<sub>week24</sub> was 63% (19/30; 95% CI, 43.9% to 80.1%) and, at data cutoff, the overall ORR was 70% (21/30; 95% CI, 50.6% to 85.3%; <xref rid="T4" ref-type="table">Table 4</xref>). The median DOR was 20.0 months (95% CI, 9.0 to 22.9 months), and the median PFS was 19.8 months (95% CI, 9.9 to 24.1 months). Overall, 30% (9/30) of patients with RCC were still receiving treatment at the time of data cutoff for this analysis.</p>
                <table-wrap id="T4" orientation="portrait" position="float">
                  <label>TABLE 4.</label>
                  <caption>
                    <p>Efficacy Outcomes (investigator review, immune-related RECIST)</p>
                  </caption>
                  <graphic xlink:href="JCO.19.01598t4"/>
                </table-wrap>
                <p>The ORR<sub>week24</sub> and overall ORR for patients with endometrial cancer were both 52% (12/23; 95% CI, 30.6% to 73.2%; <xref rid="T4" ref-type="table">Table 4</xref>). The median DOR was not reached (95% CI, 2.6 months to not evaluable [NE]), and the median PFS was 9.7 months (95% CI, 4.2 months to NE). At the time of data cutoff, 30% (7/23) of patients with endometrial cancer were still receiving treatment.</p>
                <p>Among patients with melanoma, the ORR<sub>week24</sub> and overall ORR were both 48% (10/21; 95% CI, 25.7% to 70.2%; <xref rid="T4" ref-type="table">Table 4</xref>). The median DOR was 12.5 months (95% CI, 2.7 months to NE), and the median PFS was 5.5 months (95% CI, 2.6 to 15.8 months). As of the data cutoff, 10% (2/21) of patients with melanoma remained on treatment.</p>
                <p>Patients with SCCHN achieved an ORR<sub>week24</sub> of 36% (8/22; 95% CI, 17.2% to 59.3%) and an overall ORR of 46% (10/22; 95% CI, 24.4% to 67.8%) (<xref rid="T4" ref-type="table">Table 4</xref>). The median DOR was 8.2 months (95% CI, 2.2 to 12.6 months), and the median PFS was 4.7 months (95% CI, 4.0 to 9.8 months). In total, treatment was ongoing for 14% (3/22) of patients with SCCHN at the time of data cutoff.</p>
                <p>The ORR<sub>week24</sub> and overall ORR for patients with NSCLC were both 33% (7/21; 95% CI, 14.6% to 57.0%; <xref rid="T4" ref-type="table">Table 4</xref>). The median DOR was 10.9 months (95% CI, 2.4 months to NE), and the median PFS was 5.9 months (95% CI, 2.3 to 13.8 months). Overall, 29% (6/21) of patients with NSCLC continued to receive treatment at the time of data cutoff.</p>
                <p>Patients in the urothelial cancer cohort achieved an ORR<sub>week24</sub> and overall ORR of 25% (5/20; 95% CI, 8.7% to 49.1%; <xref rid="T4" ref-type="table">Table 4</xref>). The median DOR was not reached (95% CI, 6.5 months to NE), and the median PFS was 5.4 months (95% CI, 1.3 months to NE). At the time of data cutoff, treatment was ongoing for 15% (3/20) of patients with urothelial cancer.</p>
                <p>Maximum changes in tumor size are shown in <xref ref-type="fig" rid="f1">Figure 1</xref>. Overall, 47% (65/137) of patients achieved a complete or partial response (<xref ref-type="fig" rid="f2">Fig 2</xref>). Efficacy outcomes by PD-L1 status are summarized for each tumor type in the Data Supplement.</p>
                <fig id="f1" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Maximum change in target lesion size by tumor type (investigator review, immune-related RECIST). Arrows indicate patients from phase Ib treated with lenvatinib 24 mg/day.</p>
                  </caption>
                  <graphic xlink:href="JCO.19.01598f1"/>
                </fig>
                <fig id="f2" fig-type="figure" orientation="portrait" position="float">
                  <label>FIG 2.</label>
                  <caption>
                    <p>Treatment response and duration for patients achieving a partial response or complete response (investigator review, immune-related RECIST). NSCLC, non–small-cell lung cancer; RCC, renal cell carcinoma; SCCHN, squamous cell carcinoma of the head and neck.</p>
                  </caption>
                  <graphic xlink:href="JCO.19.01598f2"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s12">
              <title>DISCUSSION</title>
              <p>In this phase Ib/II study, lenvatinib plus pembrolizumab demonstrated an acceptable safety profile and encouraging antitumor activity in patients with selected solid tumors. The MTD and recommended phase II dose were determined to be lenvatinib 20 mg once daily plus pembrolizumab 200 mg every 3 weeks.</p>
              <p>The safety profile of lenvatinib plus pembrolizumab was consistent with that observed in prior lenvatinib and pembrolizumab monotherapy trials, with no unexpected AEs.<sup><xref rid="B15" ref-type="bibr">15</xref>-<xref rid="B23" ref-type="bibr">23</xref></sup> In general, toxicities were manageable with supportive care medications, treatment interruption and discontinuation, and/or lenvatinib dose reductions.</p>
              <p>Hypothyroidism is commonly observed in patients treated with lenvatinib or pembrolizumab monotherapies.<sup><xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B22" ref-type="bibr">22</xref>-<xref rid="B24" ref-type="bibr">24</xref></sup> However, because of overlapping toxicities, the incidence of hypothyroidism was higher in patients treated with the lenvatinib plus pembrolizumab combination (42%) than in patients who received lenvatinib (16% to 35%) or pembrolizumab (6% to 10%) monotherapy in previous clinical trials.<sup><xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B22" ref-type="bibr">22</xref>-<xref rid="B24" ref-type="bibr">24</xref></sup></p>
              <p>Overall, in this study, TRAEs resulted in dose reductions and interruptions for 87 (64%) and 96 (70%) patients, respectively; the median time to dose reduction was approximately 2 months. The rates of dose reduction reported in previous clinical trials with lenvatinib monotherapy were 68% and 62% for patients with differentiated thyroid cancer and RCC, respectively.<sup><xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref></sup> Starting lenvatinib at a high dose and using dose reductions to ameliorate toxicities has been a successful strategy across several trials with lenvatinib and may contribute to the efficacy of lenvatinib. This strategy allows for strong inhibition of VEGF for several months before dose reduction (the median time to first dose reduction was 3 months in patients with differentiated thyroid cancer<sup><xref rid="B17" ref-type="bibr">17</xref></sup>). Although a significant number of patients required lenvatinib dose reductions because of TRAEs in the current study, several of these patients continued to have a durable response for several months after dose reduction.</p>
              <p>Treatment discontinuation due to TRAEs in our study was observed in 16% of patients. Similarly, Schlumberger et al<sup><xref rid="B17" ref-type="bibr">17</xref></sup> reported that 14% of patients with differentiated thyroid cancer discontinued treatment because of lenvatinib-related toxicities. In a phase II study of lenvatinib and everolimus in RCC, treatment-emergent AEs led to treatment discontinuation in 25% of patients who received single-agent lenvatinib.<sup><xref rid="B16" ref-type="bibr">16</xref></sup></p>
              <p>Across cohorts, ORRs ranged from 25% to 70%, with the most favorable responses seen among patients with RCC (70%), endometrial cancer (52%), and melanoma (48%). These encouraging response rates are particularly interesting when viewed in the context of clinical trial results with either lenvatinib or pembrolizumab given as monotherapies to patients with these tumor types. Lenvatinib monotherapy resulted in an ORR of 27% in the second-line treatment of RCC in a previously reported study.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> The Keynote 427 trial that evaluated pembrolizumab as first-line therapy in patients with advanced clear-cell RCC showed an ORR of 34%.<sup><xref rid="B25" ref-type="bibr">25</xref></sup> Additionally, response rates in our trial for patients with RCC were promising compared with the response rates of recently approved tyrosine kinase/immune checkpoint inhibitor combinations. In 2 separate phase III studies of previously untreated advanced clear-cell RCC, pembrolizumab plus axitinib showed an ORR of 59%, and avelumab plus axitinib demonstrated an ORR of 55% (in patients with PD-L1–positive tumors).<sup><xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref></sup> Our results suggest that combined inhibition of VEGF and immune checkpoint signaling pathways may result in enhanced antitumor activity in solid tumors, and in particular, advanced RCC, which is known to be sensitive to tyrosine kinase inhibitor therapy, as well as a range of other tumor types considered to be insensitive to VEGF inhibitors. Of note, the ability of lenvatinib to inhibit both FGF receptors 1-4, and VEGF receptors may contribute to the efficacy of lenvatinib plus pembrolizumab in various advanced cancers.</p>
              <p>Preclinical studies using murine tumor models demonstrated that lenvatinib pretreatment decreased immunosuppressive tumor-associated macrophages and increased interferon-γ– and granzyme B–producing CD8+ T cells, resulting in significantly greater antitumor activity compared with anti–PD-1 treatment alone. Addition of an anti–PD-1 antibody further upregulated IFN signaling pathways, promoting an angiostatic and immune-activating tumor microenvironment.<sup><xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B28" ref-type="bibr">28</xref></sup> Recent clinical trials evaluating combinations of VEGF and PD-1/PD-L1 inhibitors have shown encouraging antitumor activity for the first-line treatment of patients with metastatic RCC.<sup><xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B29" ref-type="bibr">29</xref></sup> Collectively, the results of preclinical studies and recent clinical trials of anti-VEGF and anti–PD-1/PD-L1 combination therapies provide a strong rationale for this combination.</p>
              <p>The efficacy observed in patients with advanced endometrial cancer is particularly encouraging. In this clinical trial, 48% of patients with endometrial cancer had been previously treated with systemic therapy in the metastatic setting. This cohort showed an ORR of 52% and a median PFS of 9.7 months. Interestingly, neither lenvatinib nor pembrolizumab showed particularly robust clinical activity in this patient population as monotherapies, with reported ORRs of 22% and 13%, respectively.<sup><xref rid="B30" ref-type="bibr">30</xref>,<xref rid="B31" ref-type="bibr">31</xref></sup> Although pembrolizumab is typically indicated for patients with microsatellite instability–high (MSI-H) tumors, only 25%-35% of patients with endometrial carcinoma are MSI-H.<sup><xref rid="B32" ref-type="bibr">32</xref></sup> In both the RCC and endometrial cancer cohorts, our data suggest that this treatment combination is at least additive.</p>
              <p>The Keynote 006 trial showed that pembrolizumab monotherapy in patients with advanced melanoma resulted in an ORR of 36%.<sup><xref rid="B33" ref-type="bibr">33</xref></sup> Lenvatinib monotherapy in patients with advanced melanoma resulted in an ORR of just 9.7%.<sup><xref rid="B34" ref-type="bibr">34</xref></sup> As such, the ORR of 48% in our combination of lenvatinib plus pembrolizumab represents an encouraging improvement. Additionally, one of the more striking improvements in ORR compared with pembrolizumab monotherapy occurred in the SCCHN cohort. Although the Keynote 012 clinical trial of pembrolizumab in patients with advanced SCCHN showed an ORR of 16% to 18%,<sup><xref rid="B35" ref-type="bibr">35</xref>,<xref rid="B36" ref-type="bibr">36</xref></sup> this study resulted in an ORR of 45%.</p>
              <p>Of note, PD-L1 status did not correlate with ORR in this trial. However, the sample sizes in each cohort were relatively small, and PD-L1 status was not available for several patients. PD-L1 and other biomarkers are being evaluated in ongoing phase III clinical trials with the lenvatinib plus pembrolizumab combination.</p>
              <p>Limitations of this study are typical of an early-phase clinical trial and include small numbers of patients treated, a heterogeneous patient population that was not randomly assigned, and the lack of a comparator treatment arm. Additionally, the PD-L1 status could be determined at any time point (including from archival tissue), and the PD-L1 expression assay has not yet been validated for patients with RCC, SCCHN, endometrial cancer, urothelial cancer, or melanoma.</p>
              <p>In conclusion, lenvatinib plus pembrolizumab resulted in a manageable toxicity profile and promising antitumor activity in patients with selected solid tumors. Based on the clinical activity of the combination regimen in this study, additional clinical trials for patients with gastric cancer (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03609359">NCT03609359</ext-link>), gastroesophageal cancer (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03321630">NCT03321630</ext-link>), and differentiated thyroid cancer (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02973997">NCT02973997</ext-link>) are currently under way. Furthermore, the results of this study laid the foundation for 4 large phase III clinical trials in patients with RCC (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02811861">NCT02811861</ext-link>), endometrial cancer (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03517449">NCT03517449</ext-link>), melanoma (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03820986">NCT03820986</ext-link>), and NSCLC (ClinicalTrials.gov identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03829332">NCT03829332</ext-link>), which are currently ongoing. In the future, we also plan to study lenvatinib plus pembrolizumab in patients with RCC who have had disease progression after treatment with immune checkpoint inhibitors.</p>
            </sec>
          </body>
          <back>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn specific-use="presented-at" fn-type="presented-at">
                <p>Presented at the European Society for Medical Oncology Congress, Copenhagen, Denmark, October 7-11, 2016.</p>
              </fn>
              <fn id="fn1" fn-type="trial">
                <p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02501096">NCT02501096</ext-link>.</p>
              </fn>
            </fn-group>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>We thank the patients, their families, the investigators, and the teams who participated in this trial. We also thank Emmett Schmidt, MD, PhD (Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ); Marcia Brose, MD, PhD (Department of Otorhinolaryngology – Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA); Peter Kubiak, PhD (Eisai Inc., Woodcliff Lake, NJ); and Lea Dutta, Pharm.D (Eisai Inc., Woodcliff Lake, NJ) for their contributions. This study was funded by Eisai Inc., Woodcliff Lake, NJ, and was also supported by Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ. Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by a Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). Medical writing and editorial support was provided by Oxford PharmaGenesis Inc., Newtown, PA, and was funded by Eisai Inc., Woodcliff Lake, NJ, and Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ.</p>
            </ack>
            <sec id="s14">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> All authors</p>
              <p><bold>Provision of study materials or patients:</bold> Matthew H. Taylor, Robert J. Motzer, Chung-Han Lee, Vicky Makker, Drew Rasco</p>
              <p><bold>Collection and assembly of data:</bold> Matthew H. Taylor, Robert J. Motzer, Chung-Han Lee, Vicky Makker, Drew Rasco</p>
              <p><bold>Data analysis and interpretation:</bold> All authors</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec id="s15">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec id="s16">
                <title>Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link ext-link-type="uri" xlink:href="http://www.asco.org/rwc">www.asco.org/rwc</ext-link> or <ext-link ext-link-type="uri" xlink:href="https://ascopubs.org/journal/jco/site/ifc">ascopubs.org/journal/jco/site/ifc</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link ext-link-type="uri" xlink:href="https://openpaymentsdata.cms.gov/">Open Payments</ext-link>).</p>
              </sec>
              <sec id="s17">
                <title>Matthew H. Taylor</title>
                <p><bold>Consulting or Advisory Role:</bold> Bristol-Myers Squibb, Eisai, Array BioPharma, Loxo, Bayer, ArQule, Blueprint Medicines, Novartis, Sanofi/Genzyme</p>
                <p><bold>Speakers' Bureau:</bold> Bristol-Myers Squibb, Eisai</p>
                <p><bold>Research Funding:</bold> Bristol-Myers Squibb (Inst), Merck Sharp &amp; Dohme Corp. (Inst), Pharmacyclics (Inst), AstraZeneca (Inst), Eisai (Inst), Incyte (Inst), EMD Serono (Inst), Novartis (Inst), Seattle Genetics (Inst), AbbVie (Inst), Genentech (Inst), Eli Lilly (Inst), Roche (Inst), Acerta Pharma (Inst), Genzyme Corporation (Inst), Pfizer (inst)</p>
              </sec>
              <sec id="s18">
                <title>Chung-Han Lee</title>
                <p><bold>Consulting or Advisory Role:</bold> Exelixis, Eisai, Amgen, Bristol-Myers Squibb</p>
                <p><bold>Research Funding:</bold> Pfizer (Inst), Eisai (Inst), Bristol-Myers Squibb (Inst), Calithera Biosciences (Inst), Exelixis (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Eisai</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Calithera Biosciences</p>
              </sec>
              <sec id="s19">
                <title>Vicky Makker</title>
                <p><bold>Honoraria:</bold> Eisai, Merck</p>
                <p><bold>Consulting or Advisory Role:</bold> Eisai, Merck, Karyopham, Takeda, ArQule</p>
                <p><bold>Research Funding:</bold> Lilly, AstraZeneca, Eisai, Merck, Takeda, Bristol-Myers Squibb</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Eisai, Merck, Karyopharm Therapeutics</p>
                <p><bold>Other Relationship:</bold> IBM</p>
              </sec>
              <sec id="s20">
                <title>Drew Rasco</title>
                <p><bold>Consulting or Advisory Role:</bold> Boehringer Ingelheim, Lilly</p>
                <p><bold>Research Funding:</bold> Celgene (Inst), Millennium (Inst), Rexahn Pharmaceuticals (Inst), Five Prime Therapeutics (Inst), Pharmacyclics (Inst), Asana Biosciences (Inst), Eisai (Inst), Aeglea Biotherapeutics (Inst), Merck (Inst), Ascentage Pharma (Inst), Macrogenics (Inst), Apexian Pharmaceuticals (Inst), Birdie (Inst), AbbVie (Inst), Constellation Pharmaceuticals (Inst), Syndax (Inst), Astex Pharmaceuticals (Inst), Compugen (Inst), Coordination Therapeutics (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Lilly (Inst), Boehringer Ingelheim (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Asana Biosciences, Incyte, Pfizer</p>
              </sec>
              <sec id="s21">
                <title>Corina E. Dutcus</title>
                <p><bold>Employment:</bold> Eisai</p>
              </sec>
              <sec id="s22">
                <title>Jane Wu</title>
                <p><bold>Employment:</bold> Eisai</p>
              </sec>
              <sec id="s23">
                <title>Daniel E. Stepan</title>
                <p><bold>Employment:</bold> Eisai</p>
              </sec>
              <sec id="s24">
                <title>Robert C. Shumaker</title>
                <p><bold>Employment:</bold> Eisai, RRD International (I)</p>
              </sec>
              <sec id="s25">
                <title>Robert J. Motzer</title>
                <p><bold>Consulting or Advisory Role:</bold> Pfizer, Novartis, Eisai, Exelixis, Merck, Genentech, Incyte, Lilly, Roche</p>
                <p><bold>Research Funding:</bold> Pfizer (Inst), Bristol-Myers Squibb (Inst), Eisai (Inst), Novartis (Inst), Genentech (Inst), Roche (Inst)</p>
                <p><bold>Travel, Accommodations, Expenses:</bold> Bristol-Myers Squibb</p>
                <p>No other potential conflicts of interest were reported.</p>
              </sec>
            </sec>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="B1">
                <label>1.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fontanini</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Vignati</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Boldrini</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>3</volume>
                  <fpage>861</fpage>
                  <lpage>865</lpage>
                  <year>1997</year>
                  <pub-id pub-id-type="pmid">9815760</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B2">
                <label>2.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sato</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tsuchiya</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Sasaki</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma</article-title>
                  <source>Jpn J Cancer Res</source>
                  <volume>90</volume>
                  <fpage>874</fpage>
                  <lpage>879</lpage>
                  <year>1999</year>
                  <pub-id pub-id-type="pmid">10543260</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B3">
                <label>3.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ott</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Hodi</surname>
                      <given-names>FS</given-names>
                    </name>
                    <name>
                      <surname>Buchbinder</surname>
                      <given-names>EI</given-names>
                    </name>
                  </person-group>
                  <article-title>Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data</article-title>
                  <source>Front Oncol</source>
                  <volume>5</volume>
                  <fpage>202</fpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26442214</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B4">
                <label>4.</label>
                <mixed-citation publication-type="journal">
                  <comment>Kato Y, Tabata K, Hori Y, et al: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors. Mol Cancer Ther 14, 2015 (12, suppl 2; abstr A92)</comment>
                </mixed-citation>
              </ref>
              <ref id="B5">
                <label>5.</label>
                <mixed-citation publication-type="journal">
                  <comment>Kato Y: Upregulation of memory T cell population and enhancement of Th1 response by lenvatinib potentiate antitumor activity of PD-1 signaling blockade. Cancer Res 77, 2017 (13, suppl; abstr 4614)</comment>
                </mixed-citation>
              </ref>
              <ref id="B6">
                <label>6.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matsui</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Yamamoto</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Funahashi</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition</article-title>
                  <source>Int J Cancer</source>
                  <volume>122</volume>
                  <fpage>664</fpage>
                  <lpage>671</lpage>
                  <year>2008</year>
                  <pub-id pub-id-type="pmid">17943726</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B7">
                <label>7.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matsui</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Funahashi</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Uenaka</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>14</volume>
                  <fpage>5459</fpage>
                  <lpage>5465</lpage>
                  <year>2008</year>
                  <pub-id pub-id-type="pmid">18765537</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B8">
                <label>8.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tohyama</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Matsui</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kodama</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Antitumor activity of lenvatinib (e7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models</article-title>
                  <source>J Thyroid Res</source>
                  <volume>2014</volume>
                  <elocation-id>638747</elocation-id>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">25295214</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lieu</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Heymach</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Overman</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>17</volume>
                  <fpage>6130</fpage>
                  <lpage>6139</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">21953501</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B10">
                <label>10.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bergers</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Hanahan</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Modes of resistance to anti-angiogenic therapy</article-title>
                  <source>Nat Rev Cancer</source>
                  <volume>8</volume>
                  <fpage>592</fpage>
                  <lpage>603</lpage>
                  <year>2008</year>
                  <pub-id pub-id-type="pmid">18650835</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B11">
                <label>11.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Capozzi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>De Divitiis</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ottaiano</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment</article-title>
                  <source>Cancer Manag Res</source>
                  <volume>11</volume>
                  <fpage>3847</fpage>
                  <lpage>3860</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">31118801</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B12">
                <label>12.</label>
                <mixed-citation publication-type="journal">
                  <comment> Kato Y, Bao X, Macgrath S, et al: Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol 27, 2016 (suppl 6; abstr 2PD)</comment>
                </mixed-citation>
              </ref>
              <ref id="B13">
                <label>13.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Medina</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Adams</surname>
                      <given-names>VR</given-names>
                    </name>
                  </person-group>
                  <article-title>PD-1 pathway inhibitors: Immuno-oncology agents for restoring antitumor immune responses</article-title>
                  <source>Pharmacotherapy</source>
                  <volume>36</volume>
                  <fpage>317</fpage>
                  <lpage>334</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26822752</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B14">
                <label>14.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wolchok</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Hoos</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>O’Day</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>15</volume>
                  <fpage>7412</fpage>
                  <lpage>7420</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19934295</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B15">
                <label>15.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Robert</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Schachter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Long</surname>
                      <given-names>GV</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab versus ipilimumab in advanced melanoma</article-title>
                  <source>N Engl J Med</source>
                  <volume>372</volume>
                  <fpage>2521</fpage>
                  <lpage>2532</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25891173</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B16">
                <label>16.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Motzer</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Hutson</surname>
                      <given-names>TE</given-names>
                    </name>
                    <name>
                      <surname>Glen</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>16</volume>
                  <fpage>1473</fpage>
                  <lpage>1482</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26482279</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B17">
                <label>17.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlumberger</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tahara</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wirth</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lenvatinib versus placebo in radioiodine-refractory thyroid cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>372</volume>
                  <fpage>621</fpage>
                  <lpage>630</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25671254</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B18">
                <label>18.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schlumberger</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Jarzab</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Cabanillas</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>22</volume>
                  <fpage>44</fpage>
                  <lpage>53</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26311725</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B19">
                <label>19.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Garon</surname>
                      <given-names>EB</given-names>
                    </name>
                    <name>
                      <surname>Rizvi</surname>
                      <given-names>NA</given-names>
                    </name>
                    <name>
                      <surname>Hui</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab for the treatment of non-small-cell lung cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>372</volume>
                  <fpage>2018</fpage>
                  <lpage>2028</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25891174</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B20">
                <label>20.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herbst</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Baas</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>DW</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <volume>387</volume>
                  <fpage>1540</fpage>
                  <lpage>1550</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26712084</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B21">
                <label>21.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patnaik</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Rasco</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>21</volume>
                  <fpage>4286</fpage>
                  <lpage>4293</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25977344</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B22">
                <label>22.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reck</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rodríguez-Abreu</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>AG</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>375</volume>
                  <fpage>1823</fpage>
                  <lpage>1833</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27718847</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B23">
                <label>23.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bellmunt</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>de Wit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Vaughn</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab as second-line therapy for advanced urothelial carcinoma</article-title>
                  <source>N Engl J Med</source>
                  <volume>376</volume>
                  <fpage>1015</fpage>
                  <lpage>1026</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28212060</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B24">
                <label>24.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kudo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Finn</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Qin</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial</article-title>
                  <source>Lancet</source>
                  <volume>391</volume>
                  <fpage>1163</fpage>
                  <lpage>1173</lpage>
                  <year>2018</year>
                  <pub-id pub-id-type="pmid">29433850</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B25">
                <label>25.</label>
                <mixed-citation publication-type="journal">
                  <comment>McDermott DF, Lee J-L, Szczylik C, et al: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 36, 2018 (15, suppl; abstr 4500)</comment>
                </mixed-citation>
              </ref>
              <ref id="B26">
                <label>26.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rini</surname>
                      <given-names>BI</given-names>
                    </name>
                    <name>
                      <surname>Plimack</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Stus</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>
                  <source>N Engl J Med</source>
                  <volume>380</volume>
                  <fpage>1116</fpage>
                  <lpage>1127</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">30779529</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B27">
                <label>27.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Motzer</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Penkov</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Haanen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>
                  <source>N Engl J Med</source>
                  <volume>380</volume>
                  <fpage>1103</fpage>
                  <lpage>1115</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">30779531</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B28">
                <label>28.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kato</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Tabata</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kimura</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway</article-title>
                  <source>PLoS One</source>
                  <volume>14</volume>
                  <elocation-id>e0212513</elocation-id>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">30811474</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B29">
                <label>29.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rini</surname>
                      <given-names>BI</given-names>
                    </name>
                    <name>
                      <surname>Powles</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Atkins</surname>
                      <given-names>MB</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <volume>393</volume>
                  <fpage>2404</fpage>
                  <lpage>2415</lpage>
                  <year>2019</year>
                  <pub-id pub-id-type="pmid">31079938</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B30">
                <label>30.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vergote</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Teneriello</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Powell</surname>
                      <given-names>MA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes</article-title>
                  <source>J Clin Oncol</source>
                  <volume>31</volume>
                  <fpage>5520</fpage>
                  <year>2013 </year>
                  <issue>15</issue>
                  <supplement>suppl; abstr 5520</supplement>
                </mixed-citation>
              </ref>
              <ref id="B31">
                <label>31.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ott</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Bang</surname>
                      <given-names>YJ</given-names>
                    </name>
                    <name>
                      <surname>Berton-Rigaud</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <fpage>2535</fpage>
                  <lpage>2541</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28489510</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B32">
                <label>32.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kloor</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>von Knebel Doeberitz</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>The immune biology of microsatellite-unstable cancer</article-title>
                  <source>Trends Cancer</source>
                  <volume>2</volume>
                  <fpage>121</fpage>
                  <lpage>133</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">28741532</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B33">
                <label>33.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schachter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ribas</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Long</surname>
                      <given-names>GV</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)</article-title>
                  <source>Lancet</source>
                  <volume>390</volume>
                  <fpage>1853</fpage>
                  <lpage>1862</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28822576</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B34">
                <label>34.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>O’Day</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma</article-title>
                  <source>J Clin Oncol</source>
                  <volume>31</volume>
                  <year>2013 </year>
                  <issue>15</issue>
                  <supplement>suppl; abstr 9026</supplement>
                </mixed-citation>
              </ref>
              <ref id="B35">
                <label>35.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Seiwert</surname>
                      <given-names>TY</given-names>
                    </name>
                    <name>
                      <surname>Burtness</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Mehra</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>17</volume>
                  <fpage>956</fpage>
                  <lpage>965</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27247226</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B36">
                <label>36.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Larkins</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Blumenthal</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Yuan</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy</article-title>
                  <source>Oncologist</source>
                  <volume>22</volume>
                  <fpage>873</fpage>
                  <lpage>878</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28533473</pub-id>
                </mixed-citation>
              </ref>
              <ref id="B37">
                <label>37.</label>
                <mixed-citation publication-type="other">
                  <source>Medical Dictionary for Drug Regulatory Affairs.</source>
                  <comment>
                    <ext-link ext-link-type="uri" xlink:href="www.meddra.org">www.meddra.org</ext-link>
                  </comment>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
